Back to top
more

Concert Pharmaceuticals, Inc. (CNCE)

(Delayed Data from NSDQ)

$10.65 USD

10.65
228,845

+0.69 (6.93%)

Updated May 3, 2019 04:00 PM ET

After-Market: $10.67 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales

by Zacks Equity Research

Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.

    Vertex (VRTX) Stock Up 70% in a Year's Time: Here's Why

    by Zacks Equity Research

    Vertex Pharmaceuticals' (VRTX) stock rallies on consistent expansion in patient population through label expansions of Kalydeco and Orkambi and positive data readout from pivotal studies.

      Concert Pharmaceuticals Plunges on Patent Petition Setback

      by Zacks Equity Research

      Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.

        Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session

        by Zacks Equity Research

        Concert Pharmaceuticals (CNCE) saw its shares rise nearly 6% on the day.

          Vertex Gets CHMP Recommendation for Orkambi Label Expansion

          by Zacks Equity Research

          Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.

            Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media

            by Zacks Equity Research

            Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media

              5 Stocks to Bet on New Analyst Coverage

              by Zacks Equity Research

              Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

                Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales

                by Zacks Equity Research

                Vertex Pharmaceuticals Incorporated's (VRTX) Q2 results were encouraging, as it topped earnings and revenues expectations backed by higher sales of both its CF drugs.

                  Here's Why Investors Are Glued to Vertex Pharma (VRTX) Stock

                  by Zacks Equity Research

                  Vertex Pharmaceuticals, Inc. (VRTX), has been attracting investor attention.

                    Concert Pharma Falls After Clinical Hold on Hair Loss Drug

                    by Zacks Equity Research

                    Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata.

                      Why Is Vertex Pharma (VRTX) Stock Soaring This Year?

                      by Zacks Equity Research

                      Vertex Pharmaceuticals, Inc.'s (VRTX) shares have risen 57.8% this year so far, outperforming the increase of 1.3% for the Zacks classified Large-Cap Pharma industry.

                        Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong

                        by Zacks Equity Research

                        Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.

                          Will Concert Pharmaceuticals (CNCE) Continue to Surge Higher?

                          by Zacks Equity Research

                          As of late, it has definitely been a great time to be an investor in Concert Pharmaceuticals Inc (CNCE).

                            Moving Average Crossover Alert: Concert Pharmaceuticals (CNCE)

                            by Zacks Equity Research

                            Concert Pharmaceuticals, Inc. (CNCE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

                              Arpita Dutt headshot

                              After Valeant, Here are 5 Drug Stocks Bill Ackman Should Buy Instead

                              by Arpita Dutt

                              With Bill Ackman finally deciding to exit Valeant (VRX), here is a look at 5 Zacks Rank #1 and #2 drug stocks that the billionaire investor could consider buying.

                                Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M

                                by Zacks Equity Research

                                Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.

                                  Concert's (CNCE) CTP-656 Gets Orphan Drug Status in U.S.

                                  by Zacks Equity Research

                                  Concert Pharmaceuticals, Inc. (CNCE) announced that the FDA has granted orphan drug designation to its candidate CTP-656 for the treatment of cystic fibrosis.

                                    Concert Offers Update on Cystic Fibrosis Drug, Stock Down

                                    by Zacks Equity Research

                                    Concert Pharmaceuticals, Inc. (CNCE) provided update on the development plan of its next generation CFTR potentiator, CTP-656, for the treatment of cystic fibrosis in the U.S. and Europe.

                                      Will Concert Pharmaceuticals (CNCE) Continue to Surge Higher?

                                      by Zacks Equity Research

                                      As of late, it has definitely been a great time to be an investor in Concert Pharmaceuticals Inc (CNCE)